FENNEC PHARMACEUTICALS INC.·4

May 12, 4:05 PM ET

RALLIS CHRIS A 4

4 · FENNEC PHARMACEUTICALS INC. · Filed May 12, 2026

Research Summary

AI-generated summary of this filing

Updated

Fennec (FENC) Director Chris Rallis Exercises Options, Sells Shares

What Happened
Director Chris A. Rallis exercised stock options on May 11, 2026, resulting in the acquisition of 14,344 shares at an exercise price of $2.44 per share (total cost $34,999). On the same day he sold 8,346 shares in an open-market/private sale at $7.04 per share, receiving $58,756; the sale was executed to satisfy tax withholding related to the option exercise.

Key Details

  • Transaction date: 2026-05-11; Form 4 filed 2026-05-12 (timely filing).
  • Option exercise (code M): 14,344 shares @ $2.44 = $34,999 (acquired).
  • Sale (code S): 8,346 shares @ $7.04 = $58,756 (disposed).
  • Derivative reporting: 14,344 shares shown as exercised/converted (footnote indicates conversion of options).
  • Footnotes: F1/F3 — exercise pursuant to a 10b5‑1 plan adopted May 19, 2025; F2 — shares sold to satisfy tax obligations.
  • Shares owned after the transactions: not specified in the information provided in this summary (see filing for beneficial ownership amounts).

Context
This was an option exercise combined with a routine tax‑related sale (partial cashless-like outcome): Rallis exercised options under a pre-existing 10b5‑1 plan and sold a portion of the resulting shares to cover taxes. Such transactions are common for insiders exercising options and do not, by themselves, indicate a change in company outlook.

Insider Transaction Report

Form 4
Period: 2026-05-11
Transactions
  • Exercise/Conversion

    Common Shares

    [F1]
    2026-05-11$2.44/sh+14,344$34,99971,423 total
  • Sale

    Common Shares

    [F2]
    2026-05-11$7.04/sh8,346$58,75663,077 total
  • Exercise/Conversion

    Stock Option

    [F3]
    2026-05-11$2.44/sh14,344$34,999186,189 total
    Exercise: $2.44From: 2016-06-09Exp: 2026-06-09Common shares (14,344 underlying)
Footnotes (3)
  • [F1]Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on May 19, 2025.
  • [F2]Shares sold to satisfy tax obligation on option exercise.
  • [F3]Represents options exercised pursuant to a 10b5-1 plan adopted on May 19, 2025.
Signature
/s/ Chris Rallis|2026-05-12

Documents

1 file
  • 4
    form4-05122026_040501.xmlPrimary